Methods of improving viability of organ

Administering nitric oxide to organs through a perfusion system or ventilation addresses the limitations of traditional ischemic injury treatments by improving organ survival and viability, particularly for transplantation, by maintaining mitochondrial function and reducing oxidative stress.

JP2024159817AActive Publication Date: 2024-11-08MALLINCKRODT HOSPITAL PROD IP UNLIMITED CO
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024137625
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-08-25
Filing Date
2024-08-19
Publication Date
2024-11-08
Estimated Expiration
2038-08-24

AI Technical Summary

Technical Problem

Existing methods for alleviating ischemic injury in organs, such as perfusing with oxygen, can cause significant tissue damage and are not reliable for long periods, leading to complications like brain damage during stroke or cardiac arrest, and traditional hypometabolic methods are inadequate for extended organ preservation.

Method used

Administering nitric oxide (NO) to organs via an organ perfusion system or ventilation, with concentrations of 20 ppm or less, in a sequential manner, including a loading dose followed by continuous administration, to improve organ survival and reduce ischemia-reperfusion injury.

Benefits of technology

The method significantly improves organ survival by maintaining mitochondrial function, reducing oxidative damage, and enhancing the viability of organs intended for transplantation, even in brain-dead donors, by minimizing ischemic and reperfusion injuries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159817000001_ABST
    Figure 2024159817000001_ABST
Patent Text Reader

Abstract

To provide methods of improving the viability of an organ.SOLUTION: The present disclosure provides methods of improving the viability of one or more organs by continuously administering a composition comprising NOx gas directly to the organ(s). A method of improving the viability of an organ intended for transplant comprises continuously administering a composition comprising NOx gas directly to the organ via an organ perfusion system or ventilation. The composition is administered for at least one hour but not more than 12 hours. The composition is administered after the organ has been harvested from a donor.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 550,463, filed Aug. 25, 2017, the disclosure of which is incorporated herein by reference in its entirety.

[0002] This disclosure is based on the x A method is provided for improving the viability of one or more organs by continuously administering a composition comprising a gas directly to the organ(s). [Background technology]

[0003] Cells, tissues, organs, and organisms that are deprived of adequate blood flow suffer ischemic injury due to oxidative stress and ultimately death. Traditional methods of alleviating ischemic injury include perfusing the affected tissue with oxygen, but this procedure can cause significant tissue damage, potentially resulting in serious and / or permanent injuries, such as stroke or brain damage during cardiac arrest.

[0004] Attempts have been made to reduce ischemia and reperfusion injury by inducing a hypometabolic state in tissues and organs. For example, in situations where living tissue is preserved for transplant or graft, one common method to reduce metabolic activity is by immersing the tissue or organ in a physiological fluid, such as saline, and placing it in a cold environment. However, such methods cannot be relied upon for long periods of time, and the success of organ transplantation and limb reattachment remains inversely related to the time the organ or limb is not in contact with the intact organism.

[0005] Thus, there remains a need in the art to improve organ viability prior to ischemia and / or reperfusion injury. Summary of the Invention [Means for solving the problem]

[0006] In one aspect, the present disclosure provides a method for improving the viability of an organ intended for transplantation, comprising administering NO to the organ via an organ perfusion system or ventilation. x The present invention includes methods that include direct continuous administration of a gas-containing composition.

[0007] In another aspect, the present disclosure provides a method of improving the viability of an organ injured by ischemia-reperfusion, comprising administering about 20 ppm or less NO to the organ via an organ perfusion system or ventilation. x The present invention encompasses methods comprising the direct continuous administration of a composition comprising a gas. In various embodiments, the organ in need of treatment is an organ damaged by trauma, surgery, respiratory arrest, or cardiac arrest. In certain embodiments, the organ in need of treatment is an organ intended for transplantation. In an exemplary embodiment, the organ in need of treatment is an organ intended for transplantation that has been removed from a donor.

[0008] In another aspect, the present disclosure provides a method for improving the viability of an organ injured by ischemia-reperfusion, comprising: (a) administering about 20 ppm to about 40 ppm of NO x (b) administering to the organ a composition containing the gas (a "loading dose") for up to about one hour (a "loading period"); and (b) administering to the organ via the organ perfusion system or ventilation no more than about 20 ppm NO. x The present invention encompasses methods comprising continuously administering a composition comprising a gas directly to an organ. In various embodiments, the organ in need of treatment is an organ damaged by trauma, surgery, respiratory arrest, or cardiac arrest. In certain embodiments, the organ in need of treatment is an organ intended for transplantation. In an exemplary embodiment, the organ in need of treatment is an organ intended for transplantation that has been removed from a donor.

[0009] In another aspect, the disclosure provides a method for improving the viability of an organ intended for transplantation, comprising administering to the organ via an organ perfusion system or ventilation no more than 20 ppm NO. x In some embodiments, the organ is present in a brain-dead donor. In other embodiments, the organ is present in a brain-dead donor. xIt has been removed from the donor prior to administration of the gas-containing composition, hi an exemplary embodiment, the organ is a lung, a kidney, or a heart.

[0010] In another aspect, the present disclosure provides a method for improving the viability of an organ intended for transplantation, comprising: (a) administering to the patient from about 20 ppm to about 40 ppm of NO x (b) administering to the organ a composition containing the gas (a "loading dose") for up to about one hour (a "loading period"); and (b) administering to the organ via the organ perfusion system or ventilation no more than 20 ppm NO. x The method includes administering a composition comprising NO gas directly to the organ. In some embodiments, the organ is in a brain dead donor. In other embodiments, the organ is in a brain dead donor. x It has been removed from the donor prior to administration of the gas-containing composition, hi an exemplary embodiment, the organ is a lung, a kidney, or a heart.

[0011] In another aspect, the present disclosure provides a method of treating ischemia-reperfusion injury in an organ in need thereof, comprising administering 20 ppm or less NO directly to the organ via an organ perfusion system or ventilation. x The present invention encompasses methods comprising the step of: continuously administering a composition comprising a gas. In various embodiments, the organ in need of treatment is an organ damaged by trauma, surgery, respiratory arrest, or cardiac arrest. In certain embodiments, the organ in need of treatment is an organ intended for transplantation. In an exemplary embodiment, the organ in need of treatment is an organ intended for transplantation that has been removed from a donor.

[0012] In another aspect, the present disclosure provides a method of treating ischemia-reperfusion injury in an organ in need thereof, comprising: (a) administering to an organ a concentration of about 20 ppm to about 40 ppm NO x (b) administering to the organ a composition containing the gas (a "loading dose") for up to about one hour (a "loading period"); and (b) administering to the organ via the organ perfusion system or ventilation no more than 20 ppm NO. xThe present invention encompasses methods comprising continuously administering a composition comprising a gas directly to an organ. In various embodiments, the organ in need of treatment is an organ damaged by trauma, surgery, respiratory arrest, or cardiac arrest. In certain embodiments, the organ in need of treatment is an organ intended for transplantation. In an exemplary embodiment, the organ in need of treatment is an organ intended for transplantation that has been removed from a donor.

[0013] In another aspect, the disclosure provides a method for implantation, comprising: (a) administering to the patient an amount of NOx of 20 ppm or less; x The method includes (a) administering a composition comprising a NO gas directly to an organ intended for transplantation for up to 12 consecutive hours, and (b) transplanting the organ into a recipient. In some embodiments, the organ is present in a brain-dead donor. In other embodiments, the organ is present in a brain-dead donor. x It has been removed from the donor prior to administration of the gas-containing composition, hi an exemplary embodiment, the organ is a lung, a kidney, or a heart.

[0014] In another aspect, the disclosure provides a method for implantation, comprising: (a) administering about 20 ppm to about 40 ppm NO x (b) administering to the organ a composition containing the gas (the "loading dose") for up to about one hour (the "loading period"); and then (b) administering to the organ a composition containing 20 ppm or less NO x The method includes (a) administering a composition comprising a NO gas directly to an organ intended for transplantation for up to 12 consecutive hours, and then (c) transplanting the organ into a recipient. In some embodiments, the organ is present in a brain-dead donor. In other embodiments, the organ is present in a brain-dead donor. x It has been removed from the donor prior to administration of the gas-containing composition, hi an exemplary embodiment, the organ is a lung, a kidney, or a heart.

[0015] Other aspects and iterations of the disclosure are described more thoroughly below. The present specification also provides, for example, the following items: (Item 1) A method for improving the viability of an organ intended for transplantation, comprising administering to said organ via an organ perfusion system or ventilation a concentration of 20 ppm or less NO.x The method comprises directly and continuously administering a composition comprising the gas. (Item 2) 13. The method of claim 1, wherein the composition is administered for at least 1 hour but not more than 12 hours. (Item 3) 3. The method of claim 1 or 2, wherein the composition is administered after the organ is harvested from the donor. (Item 4) 3. The method of claim 1 or 2, wherein the composition is administered while the organ is in the body of a brain-dead donor. (Item 5) 4. The method according to any one of items 1 to 3, wherein the organ is selected from the group consisting of lung, heart, liver, kidney, pancreas, intestine, thymus, and cornea. (Item 6) NO x The method according to any one of items 1 to 5, wherein the amount of is about 10 ppm to about 15 ppm. (Item 7) NO x The method according to any one of items 1 to 5, wherein the amount of is about 5 ppm to about 10 ppm. (Item 8) NO x The method according to any one of items 1 to 5, wherein the amount of is about 1 ppm to about 5 ppm. (Item 9) 9. The method of any one of items 1 to 8, wherein the composition is an organ perfusate and optionally further comprises one or more additional compound(s). (Item 10) 10. The method of claim 9, wherein the perfusion fluid is acellular perfusion fluid. (Item 11) The method comprises the step of: x Compositions containing gas ("loading dose") at 20 ppm or less of NO x 11. The method of any one of items 1 to 10, further comprising administering the composition comprising a gas to the organ for up to about 1 hour immediately prior to successive administration of the composition (the "loading period"). (Item 12) 12. The method of claim 11, wherein the loading dose composition is a perfusate. (Item 13) 13. The method of claim 12, wherein the perfusion fluid is acellular perfusion fluid. (Item 14) NO x 14. The method according to any one of items 1 to 13, wherein the total administration time of the gas does not exceed 12 hours. (Item 15) 15. The method according to any one of items 1 to 14, wherein mitochondrial function is significantly maintained. (Item 16) 16. The method of any one of items 1 to 15, wherein mitochondrial reactive oxygen species (mtROS) are reduced in the organ compared to an untreated control. (Item 17) A method for improving the survival rate of an organ damaged by ischemia-reperfusion, comprising administering to said organ 20 ppm or less of NO via an organ perfusion system. x The method comprises directly and continuously administering a composition comprising the gas. (Item 18) 18. The method of claim 17, wherein the composition is administered for at least 1 hour but not more than 12 hours. (Item 19) 19. The method of claim 17 or 18, wherein the organ is intended for transplantation and the composition is administered after the organ is harvested from the donor. (Item 20) 19. The method of claim 17 or 18, wherein the organ is intended for transplantation and the composition is administered while the organ is in the body of a brain-dead donor. (Item 21) 21. The method according to any one of items 17 to 20, wherein the organ is selected from the group consisting of lung, heart, liver, kidney, pancreas, intestine, thymus, and cornea. (Item 22) NO x 22. The method according to any one of items 17 to 21, wherein the amount of is about 10 ppm to about 15 ppm. (Item 23) NO xThe method according to any one of items 17 to 21, wherein the amount of is about 5 ppm to about 10 ppm. (Item 24) NO x 22. The method according to any one of items 17 to 21, wherein the amount of is about 1 ppm to about 5 ppm. (Item 25) 24. The method according to any one of items 17 to 23, wherein the composition is an organ perfusate and optionally further comprises one or more additional compound(s). (Item 26) 26. The method of claim 25, wherein the perfusion fluid is acellular perfusion fluid. (Item 27) The method comprises the step of: x Compositions containing gas ("loading dose") at 20 ppm or less of NO x 27. The method of any one of items 17 to 26, further comprising administering the composition comprising a gas to the organ for up to about 1 hour immediately prior to continuous administration (the "loading period"). (Item 28) 28. The method of claim 27, wherein the loading dose composition is a perfusate. (Item 29) 29. The method of claim 28, wherein the perfusion fluid is acellular perfusion fluid. (Item 30) NO x 30. The method according to any one of items 17 to 29, wherein the total administration time of the gas does not exceed 12 hours. (Item 31) 31. The method according to any one of items 17 to 30, wherein mitochondrial function is significantly maintained. (Item 32) 32. The method of any one of items 17 to 31, wherein mitochondrial reactive oxygen species (mtROS) are reduced in the organ compared to an untreated control. (Item 33) A method of transplantation comprising the steps of: (a) NOx of 20 ppm or less via an organ perfusion system x Continuously administering a composition comprising a gas directly to an organ intended for transplantation; and (b) transplanting said organ into a recipient. The method comprising: (Item 34) 34. The method of claim 33, wherein the composition is administered for at least 1 hour but not more than 12 hours. (Item 35) 35. The method of claim 33 or 34, wherein the composition is administered after the organ is harvested from the donor. (Item 36) The method of claim 33 or 34, wherein the composition is administered while the organ is in the body of a brain-dead donor. (Item 37) 37. The method according to any one of items 33 to 36, wherein the organ is selected from the group consisting of lung, heart, liver, kidney, pancreas, intestine, thymus, and cornea. (Item 38) NO x 38. The method according to any one of items 33 to 37, wherein the amount of is about 10 ppm to about 15 ppm. (Item 39) NO x The method according to any one of items 33 to 37, wherein the amount of is about 5 ppm to about 10 ppm. (Item 40) NO x The method according to any one of items 33 to 37, wherein the amount of is about 1 ppm to about 5 ppm. (Item 41) 41. The method according to any one of items 33 to 40, wherein the composition is an organ perfusate and optionally further comprises one or more additional compound(s). (Item 42) 42. The method of claim 41, wherein the perfusion fluid is acellular perfusion fluid. (Item 43) The method further comprises administering about 20 ppm to about 40 ppm NO for up to about 1 hour (the "loading period") immediately preceding step (a). x 43. The method of any one of items 33 to 42, further comprising administering to said organ a composition comprising a gas (a "loading dose"). (Item 44) 44. The method of claim 43, wherein the loading dose composition is a perfusate. (Item 45) 45. The method of claim 44, wherein the perfusion fluid is acellular perfusion fluid. (Item 46) NO x 46. ​​The method according to any one of items 33 to 45, wherein the total administration time of the gas does not exceed 12 hours. (Item 47) 47. The method according to any one of items 33 to 46, wherein mitochondrial function is significantly maintained. (Item 48) 48. The method of any one of items 33 to 47, wherein mitochondrial reactive oxygen species (mtROS) are reduced in the organ compared to an untreated control.

[0016] The application file will contain at least one photograph executed in color. Copies of this patent application publication including color photographs will be provided by the Department upon request and payment of the necessary fee. [Brief description of the drawings]

[0017] [Figure 1] 1 illustrates an embodiment of an EVLP circuit. [Diagram 2] 1 illustrates an embodiment of an EVLP circuit. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] This disclosure is based on the x Provided are methods for improving the viability of one or more organs by continuous administration of a composition comprising a gas directly to the organ(s). The disclosure encompasses methods for improving the viability of organs intended for transplantation, as well as organs with ischemia-reperfusion injury from other causes. The disclosure also provides methods for improving transplant organ performance and methods for transplantation. As used herein, "NO x The term "gas" refers to gaseous nitrogen oxides. In a preferred embodiment, NO xThe gas is gaseous nitric oxide (gNO). Non-limiting examples of additional components of the composition include inert diluent gases (e.g., helium, neon, etc.), human albumin, sodium caprylate, N-acetyl-DL-tryptophan, and oxygen gas (O 2 ) may be included. x Continuous administration of a gas-containing composition directly to an organ means that the organ produces NO during the administration period without interruption. x This means that the organ is in direct contact with the gas. The present disclosure is not limited by the type of organ. Non-limiting examples of suitable organs include liver, kidney, pancreas, heart, lung, intestine, thymus, cornea, vascularized composite allografts (e.g., face, hand, etc.), or any combination thereof. Organ viability is determined by the amount of NO x This will be an improvement over organs obtained by methods that do not involve continuous administration of a gas-containing composition directly to the organ. As used herein, the term "viability" refers to the suitability of an organ for its intended purpose. Measurements of organ viability may vary by organ type and are known in the art.

[0019] Several definitions that apply throughout this disclosure are now provided. As used herein, "about" refers to numerical values, including integers, fractions, percentages, etc., whether or not explicitly stated. The term "about" generally refers to a range of numerical values, such as ±0.5-1%, ±1-5%, or ±5-10% of the recited value, that are considered equivalent, e.g., to have the same function or result, as the cited value.

[0020] The term "comprising" means "including, but not necessarily limited to." It indicates open-ended inclusion or membership, particularly in the foregoing combinations, groups, series, etc. As used herein, the terms "comprising" and "including" are inclusive and / or open-ended and do not exclude additional, unrecited elements or method steps. The term "consisting essentially of" is more restrictive than "comprising," but is not as restrictive as "consisting of." Specifically, the term "consisting essentially of" limits membership to certain materials or steps, and those that do not materially affect the essential characteristics of the claimed invention.

[0021] As used herein, the term "ischemia-reperfusion injury" refers to damage caused by ischemia, reperfusion, or both.

[0022] As used herein, the terms "treat", "treating" or "treatment" refer to both therapeutic treatment and preventative or prophylactic measures, the purpose being to prevent or slow down (alleviate) undesirable physiological changes or disease / disorder. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stable (i.e., not worsening) state of disease, delay or slowing of disease progression, remission or alleviation of disease state, and remission (partial or complete remission), whether detectable or undetectable. "Treatment" may also mean prolonging survival compared to expected survival in the absence of treatment. Those in need of treatment include those already suffering from a disease or disorder, as well as those prone to having a disease or disorder, or those in whom a disease or disorder is to be prevented.

[0023] (a)NO x Composition containing gas According to this disclosure, NO xThe composition containing the gas is continuously administered directly to the organ. The composition of the present disclosure can be a gas or a liquid. When the composition of the present disclosure is a liquid, NO x The gas is solubilized in the liquid. In other words, "NO x The "gas-containing composition" is a solubilized NO x Similarly, "20 ppm NOx is a liquid composition. x The "gas-containing composition" is a liquid containing 20 ppm nitric oxide, and the 20 ppm nitric oxide is dissolved in the liquid. x Additionally, in embodiments where the composition is a liquid, the amount of NO administered directly to the organ is x The amount of gas dissolved in the liquid is x The amount of gas. NO x The gas may be generated and provided by any method known in the art.

[0024] In some embodiments, the composition is a gas. x In addition to the gas, the composition may further include one or more additional components, including, but not limited to, an inert diluent gas (s), e.g., helium, neon, etc., nitrogen, oxygen, and water. In an exemplary embodiment, NO x The gas is gNO. If the composition is a gas, it can be administered directly to the organ via a ventilator or any other method known in the art.

[0025] In another embodiment, the composition is a perfusion solution. The term "perfusion solution" refers to any fluid used in the preservation, perfusion, or reperfusion of a tissue or organ. Perfusion solutions are frequently sterile and isotonic. Solubilized NO xIn addition to the gas, the perfusion solution may further include one or more additional components, including, but not limited to, sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. The composition of the perfusion solution may also vary between organs. In a preferred embodiment, the perfusion solution is a cell-free perfusion solution. Such solutions may include, but are not limited to, Celsior solution, Krebs-Henseleit solution, normal saline solution, University of Wisconsin solution, St. Thomas II solution, Collins solution, Stanford solution, Perfidex, Steen Solution™, or combinations thereof. In an exemplary embodiment, the composition is a cell-free perfusion solution, and NO x The gas is gNO. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. Suitable methods for administering perfusion fluid directly to an organ are known in the art and include, but are not limited to, organ perfusion systems. The present disclosure is not limited to any particular organ perfusion system. Generally speaking, an organ perfusion system may include a pump for moving and controlling the perfusion fluid, a means for controlling the temperature of the system, a cannula, and a means for measuring physiological parameters. Non-limiting examples of organ perfusion systems are disclosed in U.S. Pat. No. 9,629,358, which is incorporated herein by reference. Non-limiting examples of organ perfusion systems are also disclosed in FIG. 1 and FIG. 2.

[0026] Therapeutically effective amounts of NO to improve organ viability x The gas is administered directly to the organ. Depending on the type or types of compositions administered, NO xDirect administration of gas may occur via an organ perfusion system, a ventilator, or any combination thereof. In embodiments using a combined organ perfusion system and ventilator, the organ perfusion system and the ventilator are used simultaneously to deliver NO x The gas-containing composition may be administered directly to the organ. Alternatively, or in addition, an organ perfusion system and a ventilator may be used in series to deliver NO x The gas-containing composition can be administered directly to an organ, for example with varying amounts of overlap between the two administration methods (e.g., no overlap, overlap of a few seconds, minutes, or hours), for example, first to a ventilator and then to a perfusion system, or vice versa.

[0027] "NO x A "therapeutically effective amount of a gas" is a gas that, when administered directly to an organ, is sufficient to improve the viability of the organ as defined herein. x The amount of NO gas that constitutes a "therapeutically effective amount" x The amount of NO will vary depending on a variety of factors and can be determined by one of skill in the art. As described in more detail below, a therapeutically effective amount of NO for the treatment of organs with ischemia-reperfusion injury can be used. x The therapeutically effective amount of NO gas is less than 20 ppm. x The gas can be administered alone or with a loading dose of NO x Can be used after administration of gas. NO x A loading dose of gas can be used to increase vasodilation of an ischemic organ and may be particularly appropriate when the compositions of the present disclosure are first contacted with the organ after it has been removed from the donor. However, NO provided in the loading dose x The amount of gas is typically sufficient to safely treat ischemia-reperfusion injury for extended periods of time (e.g., periods greater than 1 hour). x Exceeds the amount of gas.

[0028] In one or more embodiments, NO xThe gas is administered at an initial concentration, optionally increased as needed to obtain the desired effect (e.g., increased organ viability). For example, the initial nitric oxide concentration may be from about 0.05 ppm to about 50 ppm, or from about 1 ppm to about 50 ppm, and optionally increased incrementally until the desired effect is obtained or the nitric oxide threshold is met. An exemplary nitric oxide administration would begin with an initial concentration of about 1 ppm, followed by ... x It can be increased in increments of about 0.1 ppm to about 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 50 ppm and / or methemoglobin levels are less than or equal to about 5%. Alternatively, an exemplary nitric oxide administration may begin with an initial concentration of 5 ppm, followed by a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 50 ppm and / or methemoglobin levels are less than or equal to about 5%. In another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 10 ppm and is then increased to a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 50 ppm and / or methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 15 ppm and is then administered at a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 50 ppm and / or methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 20 ppm and is then administered at a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO xEnsure that concentrations do not exceed 50 ppm and / or methemoglobin levels are less than or equal to about 5%. In each of the above embodiments, administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. Alternatively, administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours.

[0029] In one or more embodiments, NO x The gas is administered at an initial concentration, optionally increased as needed to obtain the desired effect (e.g., increased organ viability). For example, the initial nitric oxide concentration may be from about 0.05 ppm to about 35 ppm, or from about 1 ppm to about 35 ppm, and optionally increased incrementally until the desired effect is obtained or the nitric oxide threshold is met. An exemplary nitric oxide administration would begin with an initial concentration of about 1 ppm, followed by ... x It can be increased in increments of about 0.1 ppm to about 5 ppm until an effect is achieved, but NO x Ensure that the concentration does not exceed 35 ppm and / or that methemoglobin levels are less than or equal to about 5%. Alternatively, an exemplary nitric oxide administration may begin with an initial concentration of 5 ppm, followed by a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that the concentration does not exceed 35 ppm and / or that methemoglobin levels are less than or equal to about 5%. In another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 10 ppm and is then increased to the desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that the concentration does not exceed 35 ppm and / or that methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 15 ppm and is then administered at a desired NO concentration. xIt can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 35 ppm and / or methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 20 ppm and is then administered at a rate of 10 ppm to achieve the desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 35 ppm and / or methemoglobin levels are less than or equal to about 5%. In each of the above embodiments, administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. Alternatively, administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours.

[0030] In one or more embodiments, NO x The gas is administered at an initial concentration, optionally increased as needed to obtain the desired effect (e.g., increased organ viability). For example, the initial nitric oxide concentration may be from about 0.05 ppm to about 20 ppm, or from about 1 ppm to about 20 ppm, and optionally increased incrementally until the desired effect is obtained or the nitric oxide threshold is met. An exemplary nitric oxide administration would begin with an initial concentration of about 1 ppm, followed by ... x It can be increased in increments of about 0.1 ppm to about 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 20 ppm and / or methemoglobin levels are less than or equal to about 5%. Alternatively, an exemplary nitric oxide administration may begin with an initial concentration of 5 ppm, followed by a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO xEnsure that the concentration does not exceed 20 ppm and / or that methemoglobin levels are less than or equal to about 5%. In another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 10 ppm and is then increased to the desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that the concentration does not exceed 35 ppm and / or that methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 15 ppm and is then administered at a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that the concentration does not exceed 20 ppm and / or that methemoglobin levels are less than or equal to about 5%. In yet another exemplary embodiment, administration of nitric oxide begins at an initial concentration of 20 ppm and is then administered at a desired NO concentration. x It can be increased in increments of 0.1 ppm to 5 ppm until an effect is achieved, but NO x Ensure that concentrations do not exceed 20 ppm and / or methemoglobin levels are less than or equal to about 5%. In each of the above embodiments, administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. Alternatively, administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours.

[0031] In one or more embodiments, NO x The gas is administered at an initial concentration for an initial period of time and then at a second, lower concentration for a second period of time to achieve the desired effect (e.g., increased organ viability). xThe gas may be administered at an initial concentration of about 20 ppm to about 40 ppm for up to about 1 hour, and then decreased to 20 ppm or less to improve organ viability. Exemplary nitric oxide administration may begin at an initial concentration of about 20 ppm to about 40 ppm, and then decreased in increments over an initial period of time until a nitric oxide concentration of 20 ppm or less is reached. The rate of decrease may or may not be constant. The nitric oxide concentration may be further adjusted as needed, for example, based on monitoring of nitric oxide markers. Alternatively, exemplary nitric oxide administration may begin at an initial concentration of about 20 ppm to about 40 ppm, and then held constant over an initial period of time, and then decreased to a nitric oxide concentration of 20 ppm or less. The nitric oxide concentration may be further adjusted as needed, for example, based on monitoring of nitric oxide markers. In each of the above embodiments, the total time of nitric oxide administration (the sum of the time of initial concentration and the time of concentration decline) may be 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours.

[0032] In each of the above embodiments, the initial nitric oxide concentration, the incremental increase or decrease in nitric oxide, the maximum nitric oxide concentration and / or threshold of nitric oxide or nitric oxide markers may vary depending on the application and / or based on the particular organ being treated. The increments may vary throughout the adjustment of the nitric oxide delivery. Nitric oxide may also be gradually decreased if monitoring indicates that nitric oxide or nitric oxide markers meet or exceed the nitric oxide threshold.

[0033] In each of the above embodiments, NO x The final NO concentration x The concentration may be adjusted incrementally by a specific percentage. Such incremental percentages are xThese may include 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 125%, 150%, 175% and 200% changes in concentration.

[0034] NO x Instead of or in addition to adjusting the concentration, NO x NO delivered directly to organs, such as by adjusting the flow of gas x By any means to adjust the amount of gas, NO x The gas dosage can be adjusted.

[0035] In further embodiments, administration of nitric oxide is adjusted based on monitoring of nitric oxide or a nitric oxide marker. As used herein, "nitric oxide marker" refers to a direct or indirect indicator of nitric oxide concentration in a fluid. For example, nitric oxide markers include, among others, methemoglobin and NO x (i.e., NO, nitrite ion (NO 2 - ), nitrate ion (NO 3 - Such adjustments may be made manually or by x The monitoring may be performed automatically by the delivery device. The NO delivery device may also generate an alarm based on the monitoring. If the monitoring device is a separate component from the NO delivery device, the monitoring device may transmit the monitoring information to the NO delivery device via any suitable wired or wireless connection. For example, if the nitric oxide or nitric oxide marker of the fluid falls below a certain threshold, the delivery of NO may be increased until the nitric oxide or nitric oxide marker of the fluid meets the threshold. Similarly, if the nitric oxide or nitric oxide marker of the fluid exceeds a certain threshold, the amount of NO administered may be decreased. Nitric oxide or nitric oxide marker may be monitored continuously or intermittently, for example at regular intervals.

[0036] In one or more embodiments, such monitoring can include monitoring methemoglobin and / or NO. These nitric oxide markers can be measured directly, by techniques such as pulse oximetry, optical measurements, or any other means that directly or indirectly measures or correlates with NO or an NO marker. For example, another measurement technique involves placing a probe in the perfusate to measure NO in the fluid. x The levels can be measured and real-time analysis of the perfusate can be provided.

[0037] In one or more embodiments, nitric oxide or nitric oxide markers are monitored by comparing the measured value of nitric oxide or nitric oxide markers to a nitric oxide threshold. The nitric oxide threshold may be a safety limit that ensures that methemoglobinemia does not occur. For example, the nitric oxide threshold may be a methemoglobin level, such as the ratio of methemoglobin to red blood cells. In exemplary embodiments, the nitric oxide threshold is in the range of about 1% to about 15% methemoglobin, or about 3% to about 10% methemoglobin. Thus, if the methemoglobin level meets or exceeds an acceptable range, such as ≦3%, ≦4%, ≦5%, ≦6%, ≦7%, ≦8%, ≦9%, ≦10%, ≦11%, or ≦12%, administration of nitric oxide may be adjusted.

[0038] Perfusate NO 2 The level of NO may also be monitored. 2 may accumulate. 2 If the concentration rises above a certain threshold, the NO delivery device can adjust the administration of NO and / or generate an alarm. 2 may also be removed using a reducing agent, a scrubber, a base, or other suitable means.

[0039] (b) Ischemia-reperfusion injury The term "ischemia-reperfusion injury" refers to injury resulting from ischemia, reperfusion, or both. Ischemia refers to insufficient blood supply to an organ, and ischemic injury occurs when blood supply to an area of ​​a tissue or organ is cut off. The act of restoring blood flow to an organ or tissue is called reperfusion, and reperfusion injury occurs as a result of restoring blood flow to a tissue or organ after ischemia. Ischemia can be the result of injury or disease suffered by an organism. Examples of specific diseases that can induce ischemia or hypoxia include, but are not limited to, trauma or surgery, respiratory or cardiac arrest, tumors, cardiac disease, and neurological diseases. Examples of specific injuries that can cause ischemic or hypoxic conditions include, but are not limited to, trauma, such as burns, cuts, amputations, gunshot wounds, or surgical trauma. In addition, injury can also include injury within the body, such as a stroke or heart attack, which causes a sudden drop in circulation. Other insults include reduced circulation due to non-invasive stresses such as exposure to cold or radiation, or deliberate reduction in circulation, such as during cardiac surgery or preparation of an organ donor prior to removal of the donor organ for transport and transplantation into a recipient.

[0040] One aspect of the present disclosure includes a method of treating ischemia-reperfusion injury in an organ in need thereof. The method comprises administering 20 ppm or less NO x The method includes continuously administering a composition comprising the gas directly to the organ. In some embodiments, the composition comprises 1 ppm to 20 ppm of nitric oxide. In other embodiments, the composition comprises about 1 ppm to about 10 ppm of nitric oxide, about 5 ppm to about 15 ppm of nitric oxide, or about 10 ppm to 20 ppm. In other embodiments, the composition comprises about 1 ppm, about 2 ppm, about 3 ppm, about 4 ppm, about 5 ppm, about 6 ppm, about 7 ppm, about 8 ppm, about 9 ppm, about 10 ppm, about 11 ppm, about 12 ppm, about 13 ppm, about 14 ppm, about 15 ppm, about 16 ppm, about 17 ppm, about 18 ppm, about 19 ppm, or about 20 ppm of nitric oxide. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion solution, and even more preferably, a cell-free perfusion solution. In a further embodiment, the cell-free perfusion solution is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. In various embodiments, the organ in need of treatment is an organ damaged by trauma, surgery, respiratory arrest, or cardiac arrest. In certain embodiments, the organ in need of treatment is an organ intended for transplantation. In an exemplary embodiment, the organ in need of treatment is an organ intended for transplantation that has been removed from a donor.

[0041] Administration may be for 5, 10, 15, 30 or 60 minutes. Alternatively, administration may be for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours or longer. In embodiments where the organ is intended for transplantation, NO x The administration of gas is preferably not to exceed 12 hours in total. In certain embodiments, administration begins simultaneously with ischemia. In other embodiments, administration begins some time after ischemia begins, but preferentially begins as close as possible to the onset of ischemia. For example, administration may begin about 5, 10, 15, 20, 25, or 30 minutes after the onset of ischemia. Administration may also begin during reperfusion or, alternatively, continue after reperfusion begins. In some cases, administration may continue for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more hours after reperfusion begins.

[0042] Effective treatment of ischemia-reperfusion injury can be assessed by any method known in the art, including, but not limited to, measurements of cellular function (e.g., metabolic capacity, ATP content, etc.), measurements of cellular damage (e.g., histological evaluation, protein oxidation, morphological changes, etc.), measurements of inflammation, and / or measurements of organ function.

[0043] In a further embodiment, the method of treating ischemia-reperfusion injury in an organ in need thereof comprises administering about 20 ppm to about 40 ppm NO x The composition containing the gas (the "loading dose") contains no more than 20 ppm NO x The method may include an additional step of administering a gas-containing composition for up to about 1 hour (the "loading period") immediately prior to administration. For example, the loading dose may be administered for about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, or between about 10 and about 30 minutes. In another example, the loading dose may be administered for about 30 minutes, about 35 minutes, about 40 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes. The two compositions may be the same, except for the nitric oxide concentration. Alternatively, the two compositions may be different. The concentration of nitric oxide in the loading dose may be gradually decreased over the loading period until the nitric oxide concentration is 20 ppm or less. The rate of decrease may or may not be constant. Alternatively, the concentration of nitric oxide in the loading dose may be held constant over the loading period and then decreased to a nitric oxide concentration of 20 ppm or less. In a preferred embodiment, the two compositions are the same and the composition is a perfusate, preferably a cell-free perfusate. In an exemplary embodiment, the organ is a heart, lung, or kidney, and the organ is intended for transplantation.

[0044] Another aspect of the present disclosure includes a method for improving the survival rate of an organ damaged by ischemia-reperfusion, the method comprising administering 20 ppm or less NO x The method includes continuously administering a composition comprising the gas directly to the organ. In some embodiments, the composition comprises 1 ppm to 20 ppm of nitric oxide. In other embodiments, the composition comprises about 1 ppm to about 10 ppm of nitric oxide, about 5 ppm to about 15 ppm of nitric oxide, or about 10 ppm to 20 ppm. In other embodiments, the composition comprises about 1 ppm, about 2 ppm, about 3 ppm, about 4 ppm, about 5 ppm, about 6 ppm, about 7 ppm, about 8 ppm, about 9 ppm, about 10 ppm, about 11 ppm, about 12 ppm, about 13 ppm, about 14 ppm, about 15 ppm, about 16 ppm, about 17 ppm, about 18 ppm, about 19 ppm, or about 20 ppm of nitric oxide. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion solution, and even more preferably, a cell-free perfusion solution. In a further embodiment, the cell-free perfusion solution is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. Improving the viability of an organ damaged by ischemia and / or reperfusion may include maintaining mitochondrial function or reducing oxidative damage. Other means known in the art for assessing organ viability may also be used, including, but not limited to, measuring cellular function (e.g., metabolic capacity, ATP content, etc.), measuring cellular damage (e.g., histological evaluation, morphological changes, etc.), measuring inflammation, and / or measuring organ function.

[0045] In one embodiment, the present disclosure encompasses a method for maintaining mitochondrial function in an organ with ischemia-reperfusion injury. As used herein, mitochondrial function can be measured by the respiratory control ratio (RCR), which is an index of mitochondrial coupling state. Generally speaking, RCR represents the ratio of the oxidation rate in the presence of excess substrate and adenosine diphosphate (state 3) to the oxidation rate after ADP is phosphorylated to a steady-state concentration (state 4). In some embodiments, the method comprises administering 20 ppm or less of NO to the organ. x By administering a composition comprising a gas directly to an organ, mitochondrial function is significantly preserved in an organ that has been subjected to ischemia-reperfusion injury. As used herein, "significantly preserved" refers to the NO gas-containing composition described herein. x 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% difference in mitochondrial function between organs treated with NO gas and control organs that did not undergo ischemia-reperfusion. In other words, significantly preserved indicates less than a ... x It may be shown that mitochondrial function is improved compared to similar organs that are not gassed. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0046] In another embodiment, the present disclosure encompasses a method of reducing oxidative damage to an organ suffering from ischemia-reperfusion injury. Generally speaking, the method comprises administering 20 ppm or less NO x As used herein, "reduction of oxidative damage" or "reduction of oxidative damage" may be measured in comparison to an organ treated under similar conditions, but it may be measured by administering directly and continuously a composition containing NO gas to the organ. x For example, oxidative damage may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to organs treated under similar conditions, which may be directly and continuously administered NO x In certain embodiments, mitochondrial reactive oxygen species (mtROS) are increased by direct continuous NO gas compared to untreated controls. x is reduced in ischemia-reperfusion injured organs to which NO is administered. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0047] In some embodiments, the present disclosure encompasses a method of increasing the activity of superoxide dismutase 2 (SOD2 or manganese-dependent superoxide dismutase (MnSOD)) in an organ having ischemia-reperfusion injury. The method comprises administering 20 ppm or less of NO x The method includes directly and continuously administering a composition comprising NO gas to an organ, and the activity of MnSOD is increased in the organ compared to a control organ not contacted with the composition of the present disclosure. For example, the activity of MnSOD may be increased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to an organ treated under similar conditions, which is directly and continuously administered NO gas. x No gas is administered. Methods for measuring MnSOD activity are known in the art. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0048] In another embodiment, the disclosure encompasses a method for inhibiting the formation of nitrotyrosine in an organ having ischemia-reperfusion injury. The method comprises administering 20 ppm or less of NO x The present invention relates to a method for treating a subject with a composition comprising a NO gas, the method comprising the steps of: directly and continuously administering to an organ a composition comprising a NO gas, the formation of nitrotyrosine adducts in the organ being inhibited as compared to a control organ not contacted with the composition of the present invention. For example, the formation of nitrotyrosine may be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% as compared to an organ treated under similar conditions, which may be achieved by directly and continuously administering to the organ a composition comprising a NO gas, the formation of nitrotyrosine adducts in the organ being inhibited as compared to a control organ not contacted with the composition of the present invention. x No gas is administered. Methods for measuring the formation of nitrotyrosine adducts are known in the art. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0049] In certain embodiments, the present disclosure encompasses a method for preventing the inactivation of mitochondrial complex I activity, complex II activity, complex III activity, complex IV activity, or a combination thereof, in an organ having ischemia-reperfusion injury. The method comprises administering 20 ppm or less NO x The method comprises administering a gas-containing composition directly to the organ, the gas being at or below 20 ppm NO x Administering the gas prevents inactivation of mitochondrial complex I, complex II, complex III, complex IV, or a combination thereof, compared to a control organ. In one embodiment, the gas is administered at 20 ppm or less NO x Continuous administration of a composition containing the gas directly to the organ prevents inactivation of mitochondrial complex I activity. In another embodiment, no more than 20 ppm NO x Continuous administration of the gas-containing composition directly to the organ prevents inactivation of mitochondrial complex II activity. x Continuous administration of a composition containing the gas directly to the organ prevents inactivation of mitochondrial complex III activity. In another embodiment, the composition contains no more than 20 ppm NO x Continuous administration of a gas-containing composition directly to the organ prevents the inactivation of mitochondrial complex IV activity. In a preferred embodiment, the gas-containing composition is administered at 20 ppm or less NO x Continuous administration of the gas-containing composition directly to the organ prevents the inactivation of mitochondrial complex I and mitochondrial complex II activity. In another preferred embodiment, the gas-containing composition is administered at 20 ppm or less NO xContinuous administration of a composition containing NO gas directly to the organ prevents inactivation of mitochondrial complex II and mitochondrial complex III activity. For example, inactivation of activity in each of the above embodiments may be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to organs treated under similar conditions, which is achieved by directly and continuously administering NO gas to the organ. x No gas is administered. Methods for measuring mitochondrial complex I activity, complex II activity, complex III activity, or complex IV activity are known in the art. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0050] In each of the above embodiments, 20 ppm or less NO x The administration of the gas-containing composition may be for a period of time necessary to improve the viability of the organ. For example, in some embodiments, administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. In other embodiments, administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, or longer. In embodiments where the organ is intended for transplantation, NO xThe administration of gas is preferably not to exceed 12 hours in total. In certain embodiments, administration begins simultaneously with ischemia. In other embodiments, administration begins some time after ischemia begins, but preferentially begins as close as possible to the onset of ischemia. In some embodiments, administration begins about 5, 10, 15, 20, 25, or 30 minutes after the onset of ischemia. Administration can also begin during reperfusion or, alternatively, continue after reperfusion begins. In some cases, administration can continue for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more hours after reperfusion begins.

[0051] In a further embodiment, the method comprises the step of: x The composition containing the gas (the "loading dose") contains no more than 20 ppm NO x The method may include an additional step of administering the gas-containing composition for up to about 1 hour immediately prior to administering the gas-containing composition. For example, the loading dose may be administered for about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, or for about 10 to about 30 minutes. In another example, the loading dose may be administered for about 30 minutes, about 35 minutes, about 40 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or for 30 to 60 minutes. The two compositions may be the same, except for the nitric oxide concentration. Alternatively, the two compositions may be different. The concentration of nitric oxide in the loading dose may be gradually decreased over a period of up to about 1 hour until the nitric oxide concentration is 20 ppm or less. The rate of decrease may or may not be constant. Alternatively, the concentration of nitric oxide in the loading dose may be held constant for a period of up to about 1 hour and then decreased to a nitric oxide concentration of 20 ppm or less. In a preferred embodiment, the two compositions are the same, and the composition is a perfusion fluid, preferably an acellular perfusion fluid. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally containing sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. In an exemplary embodiment, the organ is a heart, a lung, or a kidney.

[0052] (c) A method for improving the survival rate of organs intended for transplantation. Organs with ischemia-reperfusion injury include organs intended for transplantation. Thus, the present disclosure includes methods for improving the survival rate of organs intended for transplantation. Such methods include administering NO x The method includes administering a composition comprising the gas directly to the organ via an organ perfusion system or ventilation for up to 12 hours continuously. In other words, the organ is maintained in a state in which the gas is not released from the organ from the time of procurement to the time of transplantation into the recipient. x The gas is in direct contact with the organ and is not interrupted. As used herein, procurement refers to both the identification of the organ donor and the removal of the organ, and can be used interchangeably with either term. In some embodiments, the composition is administered after the organ is taken from the donor. In other embodiments, the composition is administered while the organ is in the donor's body. In these embodiments, the donor can be a brain-dead donor or a cardiac arrest donor. In some examples, administration can be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. In other examples, administration can be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, or longer. NO xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusate, and even more preferably, is a cell-free perfusate. In a further embodiment, the cell-free perfusate is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. Without wishing to be bound by theory, it is believed that the disclosed method can increase the number of organs available for transplantation by improving the viability of organs that previously did not meet the criteria for transplantation, thereby allowing the use of more organs from more donors (e.g., brain-dead related donors, non-heart-beating donors, etc.). Improving organ viability for transplantation purposes may include, in part, maintaining mitochondrial function or reducing oxidative damage to the organ. Other means known in the art for assessing organ viability may also be used, including, but not limited to, measuring cellular function (e.g., metabolic capacity, ATP content, etc.), measuring cellular damage (e.g., histological evaluation, morphological changes, etc.), measuring inflammation, and / or measuring organ function. In an exemplary embodiment, the organ is a heart, lung, or kidney.

[0053] In one embodiment, the present disclosure encompasses a method for maintaining mitochondrial function in an organ intended for transplantation. As used herein, mitochondrial function can be measured by the respiratory control ratio (RCR), which is an index of mitochondrial coupling state. Generally speaking, RCR represents the ratio of the oxidation rate in the presence of excess substrate and adenosine diphosphate (state 3) to the oxidation rate after ADP is phosphorylated to a steady-state concentration (state 4). In some embodiments, the method comprises administering 20 ppm or less of NO to the organ. x By administering a composition comprising a gas directly to the organ, mitochondrial function is significantly preserved in the organ intended for transplantation. As used herein, "significantly preserved" refers to the function of the NO gas as described herein. x Gas-treated organs and NO xIn other words, significantly maintained indicates less than a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% difference in mitochondrial function between organs that have undergone a similar ischemia-reperfusion injury but not directly and continuously treated with NO gas. x It may be shown that mitochondrial function is improved compared to similar organs intended for transplant that are not gassed. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0054] In certain embodiments, the present disclosure encompasses a method for reducing oxidative damage to an organ intended for transplantation. For example, mitochondrial reactive oxygen species (mtROS) can be reduced in an organ intended for transplantation. Such a method can include administering 20 ppm or less NO x The direct continuous administration of a composition comprising a gas to the organ can occur before the organ is removed from the donor, during transportation / storage, during transplantation into the recipient, after transplantation into the recipient, or any combination thereof. In a preferred embodiment, the organ is not exposed to NO gas from the time of removal until the time of transplantation into the recipient. x As used herein, "reduction of oxidative damage" or "reduction of oxidative damage" may be measured in comparison to organs treated under similar conditions, but without direct and continuous NO gas contact. x For example, oxidative damage may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to organs treated under similar conditions, which may be directly and continuously administered NO xIn certain embodiments, mitochondrial reactive oxygen species (mtROS) are increased directly and sequentially by NO compared to untreated controls. x is reduced in ischemia-reperfusion injured organs to which NO is administered. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0055] In some embodiments, the present disclosure encompasses a method for increasing the activity of superoxide dismutase 2 (SOD2 or manganese-dependent superoxide dismutase (MnSOD)) in an organ intended for transplantation. The method comprises administering 20 ppm or less NO x The method includes directly and continuously administering a composition comprising NO gas to an organ, and the activity of MnSOD is increased in the organ compared to a control organ not contacted with the composition of the present disclosure. For example, the activity of MnSOD may be increased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to an organ treated under similar conditions, which is directly and continuously administered NO gas. x The organ is not administered NO gas. Direct, continuous administration can occur before the organ is removed from the donor, during transport / storage, during transplantation into the recipient, after transplantation into the recipient, or any combination thereof. In a preferred embodiment, the organ is not administered NO gas from the time of removal until the time of transplantation into the recipient. x It is in direct contact with the gas and is not interrupted. Methods for measuring the activity of MnSOD are known in the art. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0056] In another embodiment, the disclosure encompasses a method for inhibiting the formation of nitrotyrosine in an organ intended for transplantation. The method comprises administering 20 ppm or less of NO x The present invention includes directly and continuously administering a composition comprising NO gas to an organ, whereby the formation of nitrotyrosine adducts in the organ is inhibited, as compared to a control organ not contacted with the composition of the present disclosure. For example, the formation of nitrotyrosine may be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, as compared to an organ treated under similar conditions, which is directly and continuously administered NO gas. x The organ is not administered NO gas. Direct, continuous administration can occur before the organ is removed from the donor, during transport / storage, during transplantation into the recipient, after transplantation into the recipient, or any combination thereof. In a preferred embodiment, the organ is not administered NO gas from the time of removal until the time of transplantation into the recipient. x The gas is directly contacted and not interrupted. Methods for measuring the formation of nitrotyrosine adducts are known in the art. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0057] In certain embodiments, the present disclosure encompasses a method for preventing inactivation of mitochondrial complex I activity, complex II activity, complex III activity, complex IV activity, or a combination thereof, in an organ intended for transplantation. The method comprises administering 20 ppm or less NO x The method comprises administering a gas-containing composition directly to the organ, the gas being at or below 20 ppm NO x Administering the gas prevents inactivation of mitochondrial complex I, complex II, complex III, complex IV, or a combination thereof, compared to a control organ. In one embodiment, the gas is administered at 20 ppm or less NO x Continuous administration of a composition containing the gas directly to the organ prevents inactivation of mitochondrial complex I activity. In another embodiment, no more than 20 ppm NO x Continuous administration of a composition containing the gas directly to the organ prevents the inactivation of mitochondrial complex II activity. x Continuous administration of a composition containing the gas directly to the organ prevents inactivation of mitochondrial complex III activity. In another embodiment, the composition contains no more than 20 ppm NO x Continuous administration of a gas-containing composition directly to the organ prevents the inactivation of mitochondrial complex IV activity. In a preferred embodiment, the gas-containing composition is administered at 20 ppm or less NO x Continuous administration of the gas-containing composition directly to the organ prevents the inactivation of mitochondrial complex I and mitochondrial complex II activity. In another preferred embodiment, the gas-containing composition is administered at 20 ppm or less NO x Continuous administration of a composition containing NO gas directly to the organ prevents inactivation of mitochondrial complex II and mitochondrial complex III activity. For example, inactivation of activity in each of the above embodiments may be inhibited by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to organs treated under similar conditions, which is achieved by directly and continuously administering NO gas to the organ. xThe organ is not administered NO gas. Direct, continuous administration can occur before the organ is removed from the donor, during transport / storage, during transplantation into the recipient, after transplantation into the recipient, or any combination thereof. In a preferred embodiment, the organ is not administered NO gas from the time of removal until the time of transplantation into the recipient. x The NO gas is directly in contact with the blood and is not interrupted. Methods for measuring mitochondrial complex I activity, complex II activity, complex III activity, or complex IV activity are known in the art. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0058] In each of the above methods, NO is delivered to the organ via the organ perfusion system. x Direct administration of the gas-containing composition can occur over 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours via an organ perfusion system, a ventilator, or any combination thereof. In embodiments using a combination organ perfusion system and a ventilator, the organ perfusion system and the ventilator can be used simultaneously to deliver NO x The gas-containing composition may be administered directly to the organ. Alternatively, or in addition, an organ perfusion system and a ventilator may be used in series to deliver NO x The gas-containing composition can be administered directly to an organ, for example with varying amounts of overlap between the two administration methods (e.g., no overlap, overlap of a few seconds, minutes, or hours), for example, first to a ventilator and then to a perfusion system, or vice versa.

[0059] In a further embodiment, the method comprises the step of: x The composition containing the gas (the "loading dose") contains no more than 20 ppm NO xThe gas-containing composition is administered up to about 1 hour before the administration of NO x The administration of gas can include additional steps, not to exceed 12 hours in total. For example, the loading dose can be administered for about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, or between about 10 minutes and about 30 minutes, in which case no more than 20 ppm NO x The gas-containing composition is administered for about 11.8 hours or less. In another example, the loading dose may be administered for about 30 minutes, about 35 minutes, about 40 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes, where the gas-containing composition is administered for about 11.8 hours or less, and the loading dose is ...5 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes, where the gas x The composition comprising the gas is administered for 11.5 hours or less. The two compositions may be the same, except for the nitric oxide concentration. Alternatively, the two compositions may be different. The concentration of nitric oxide in the loading dose may be gradually decreased over a period of up to about 1 hour until the nitric oxide concentration is 20 ppm or less. The rate of decrease may or may not be constant. Alternatively, the concentration of nitric oxide in the loading dose may be held constant for a period of up to about 1 hour, and then decreased to a nitric oxide concentration of 20 ppm or less. In a preferred embodiment, the two compositions are the same, and the composition is a perfusate, preferably a cell-free perfusate. In a further embodiment, the cell-free perfusate is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. In an exemplary embodiment, the organ is a heart, a lung, or a kidney.

[0060] (d) A method for improving the post-transplant performance of an organ intended for transplantation. Another aspect of the present disclosure includes a method for improving the post-transplant performance of an organ intended for transplantation. The method comprises administering 20 ppm or less NO x The method includes administering a composition comprising the gas directly to the organ via an organ perfusion system for up to 12 consecutive hours. In some examples, administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. In other examples, administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusate, and even more preferably a cell-free perfusate. Improving the post-transplant performance of an organ intended for transplantation may include maintaining mitochondrial function or reducing oxidative damage. Other means known in the art for assessing organ viability may also be used, including, but not limited to, measuring cellular function (e.g., metabolic capacity, ATP content, etc.), measuring cellular damage (e.g., histological evaluation, morphological changes, etc.), measuring inflammation, and / or measuring organ function. In an exemplary embodiment, the organ is the heart, lung, or kidney.

[0061] In one embodiment, the present disclosure encompasses a method for maintaining mitochondrial function in a transplanted organ. As used herein, mitochondrial function can be measured by the respiratory control ratio (RCR), which is an index of mitochondrial coupling state. Generally speaking, RCR represents the ratio of the oxidation rate in the presence of excess substrate and adenosine diphosphate (state 3) to the oxidation rate after ADP is phosphorylated to a steady-state concentration (state 4). In some embodiments, the RCR is measured by administering 20 ppm or less of NO to the organ. x By administering a composition comprising a gas directly to the organ, mitochondrial function is significantly preserved in the organ after transplantation. As used herein, "significantly preserved" refers to the function of the NO gas as described herein. x Gas-treated organs and NO x 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% difference in mitochondrial function between control organs that have undergone a similar ischemia-reperfusion injury but not directly and continuously treated with NO gas. x It may be shown that mitochondrial function is improved compared to similar organs that are not gassed. xSuitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0062] In another embodiment, the present disclosure encompasses a method for reducing oxidative damage in an organ following transplantation. Generally speaking, the method comprises administering 20 ppm or less NO x As used herein, "reduction of oxidative damage" or "reduction of oxidative damage" may be measured in comparison to an organ treated under similar conditions, but it may be measured by administering directly and continuously a composition containing NO gas to the organ. x For example, oxidative damage may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% compared to organs treated under similar conditions, which may be directly and continuously administered NO x In certain embodiments, mitochondrial reactive oxygen species (mtROS) are increased by direct continuous NO gas compared to untreated controls. x is reduced in transplanted organs to which NO was administered. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion fluid, even more preferably an acellular perfusion fluid, and the organ is the heart, lung, or kidney. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0063] In a further embodiment, the method comprises the step of: x The composition containing the gas (the "loading dose") contains no more than 20 ppm NO x The gas-containing composition is administered up to about 1 hour before the administration of NOx The administration of gas can include additional steps, not to exceed 12 hours in total. For example, the loading dose can be administered for about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, or between about 10 minutes and about 30 minutes, in which case no more than 20 ppm NO x The gas-containing composition is administered for about 11.8 hours or less. In another example, the loading dose may be administered for about 30 minutes, about 35 minutes, about 40 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes, where the gas-containing composition is administered for about 11.8 hours or less, and the loading dose is ...5 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes, where the gas x The composition comprising the gas is administered for 11.5 hours or less. The two compositions may be the same, except for the nitric oxide concentration. Alternatively, the two compositions may be different. The concentration of nitric oxide in the loading dose may be gradually decreased over a period of up to about 1 hour until the nitric oxide concentration is 20 ppm or less. The rate of decrease may or may not be constant. Alternatively, the concentration of nitric oxide in the loading dose may be held constant for a period of up to about 1 hour, and then decreased to a nitric oxide concentration of 20 ppm or less. In a preferred embodiment, the two compositions are the same, and the composition is a perfusate, preferably a cell-free perfusate. In an exemplary embodiment, the organ is a heart, lung, or kidney. In a further embodiment, the cell-free perfusate is Steen Solution™, optionally including sodium caprylate, N-acetyl-DL-tryptophan, and human albumin.

[0064] (e) Transplant method In another aspect, the present disclosure provides a method of implantation, the method comprising: (a) administering to the patient an amount of NOx of 20 ppm or less; xThe method includes (a) administering a composition comprising the gas directly to an organ intended for transplantation for up to 12 consecutive hours, and (b) transplanting the organ into a recipient. The administration may be for 5 minutes, 10 minutes, 15 minutes, 30 minutes, or 60 minutes. Alternatively, the administration may be for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours. In some embodiments, the composition comprises 1 ppm to 20 ppm of nitric oxide. In other embodiments, the composition comprises about 1 to about 10 ppm of nitric oxide, about 5 ppm to about 15 ppm of nitric oxide, or about 10 ppm to 20 ppm. In other embodiments, the composition comprises about 1 ppm, about 2 ppm, about 3 ppm, about 4 ppm, about 5 ppm, about 6 ppm, about 7 ppm, about 8 ppm, about 9 ppm, about 10 ppm, about 11 ppm, about 12 ppm, about 13 ppm, about 14 ppm, about 15 ppm, about 16 ppm, about 17 ppm, about 18 ppm, about 19 ppm, or about 20 ppm of nitric oxide. x Suitable compositions comprising the gas are described in section (a). In a preferred embodiment, the composition is a perfusion solution, and even more preferably, is an acellular perfusion solution. In a further embodiment, the acellular perfusion solution is Steen Solution™, optionally comprising sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. In an exemplary embodiment, the organ is a heart, lung, or kidney.

[0065] In certain embodiments, the organ intended for transplantation is removed from the donor before step (a) above. In these embodiments, administration begins some time after the onset of ischemia, but preferentially begins as close as possible to the onset of ischemia. For example, administration may begin about 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes after the onset of ischemia. The timing of administration may or may not correspond to the onset of reperfusion.

[0066] In a further embodiment, the method comprises the step of: x The composition containing the gas (the "loading dose") contains no more than 20 ppm NO xThe method may include an additional step of administering a gas-containing composition for up to about 1 hour (the "loading period") immediately prior to administration. For example, the loading dose may be administered for about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, or between about 10 and about 30 minutes. In another example, the loading dose may be administered for about 30 minutes, about 35 minutes, about 40 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or between 30 and 60 minutes. The two compositions may be the same, except for the nitric oxide concentration. Alternatively, the two compositions may be different. The concentration of nitric oxide in the loading dose may be gradually decreased over the loading period until the nitric oxide concentration is 20 ppm or less. The rate of decrease may or may not be constant. Alternatively, the concentration of nitric oxide in the loading dose may be held constant over the loading period and then decreased to a nitric oxide concentration of 20 ppm or less. In a preferred embodiment, the two compositions are the same, and the composition is a perfusion fluid, preferably an acellular perfusion fluid. In a further embodiment, the acellular perfusion fluid is Steen Solution™, optionally containing sodium caprylate, N-acetyl-DL-tryptophan, and human albumin. In an exemplary embodiment, the organ is a heart, a lung, or a kidney.

[0067] Working Example The following examples illustrate various iterations of the present invention.

[0068] Example 1: Lung Transplant Protocol The study will include a total of 20 lungs (8 lungs with gNO and perfusate, 8 lungs with perfusate only, and 4 lungs with gNO ventilation and perfusate) following modified standard lung donor selection criteria. A 3-arm study will include gNO added to the perfusate, perfusate only, and gNO ventilation and perfusate (pilot study). The XVivo perfusion device system with acellular perfusate (Steen solution) will be used. The maximum cold ischemia time of the lungs will be 8-10 hours. The duration of Ex-Vivo lung perfusion will be up to 12 hours. Lung health will be assessed by a grading system, biomarker evaluation, and histopathological evaluation.

[0069] Rating System The rating system involves a rating of 0 to 10 (total score) using a composite scale of three variables: 1) delta PaO, weighted as 0 to 4 using four categories; 2 1) pulmonary static compliance weighted as 0 to 4 (change from baseline): 0 = no improvement or worsening in compliance; 1 = 1 to 3% improvement; 2 = 4 to 7% improvement; 3 = 8 to 11% improvement, and 4 = 12 to 15% improvement in compliance; and 3) pulmonary vascular resistance (PVR) weighted as 0 to 2: 0 = no change in PVR or increase in PVR, 1 = 1 to 7% decrease in PVR; 2 = 8 to 15% decrease in PVR.

[0070] Biomarker evaluation Biomarkers evaluated include damage assessing protein (DAMP), high mobility group box-1 (HMGB1), S100A8 (MRP8, calgranulin A), S100A9 (MRP14, calgranulin B), and serum amyloid A (SAA). Cytokines of interest are TNFα-1, IL1-β, IL-6, NLRP3, IL-10, and donor cell-free DNA.

[0071] Histopathological evaluation Histopathological parameters evaluated are interstitial and intraalveolar edema, hyaline membrane formation, and evidence of vascular integrity / damage (CD31 staining).

[0072] Donor lung procurement Current clinical practice after organ retrieval from a donor is for static preservation at low temperature until transplantation into a recipient. During retrieval, the lung undergoes a low temperature lung flush using a low potassium dextran preservation solution in combination with topical cooling and lung ventilation. The lung is then transported at 4°C in a statically inflated state. Hypothermia reduces metabolic activity in the face of ischemia, essentially slowing down the process of cell death (5% of metabolic rate at 37°C) while preserving cell viability. Thus, hypothermic storage is the mainstay of lung preservation in the prior art. However, there is a significant reduction in metabolic function of the organ, thus preventing meaningful lung evaluation and recovery.

[0073] The donor lung procurement technique for this study was as follows: Bronchoscopy and median sternotomy were performed; the pericardium and multiple cavities were opened; both lungs were refilled and maintained at 100% FiO 2 PO in the challenge 2 Evaluate for pulmonary artery deficiency. Heparinize the system. Place a purse string suture in the main pulmonary artery (PA). Cannulate the PA through the purse string. Deflate the cannula and connect to deflated Perfadex tubing (the Perfadex bag should only drain by gravity (non-pressurized) and the bag should not be more than 1 meter above the lungs). Administer 500mcg of Alprostidil directly into the main PA. Ligate the superior vena cava (SVC), patent left and right atria, and cross-clamp aorta.

[0074] Deliver 4 liters of antegrade Perfadex. Ensure rapid drainage of both right and left atria. Place ice topically on both lungs (but only one lung per cycle). FiO2 on room air at a tidal volume of 4-6 ml / kg / min and a respiratory rate of 10 breaths per minute. 2Maintain ventilation at 100%. Once infusion is complete, excise the heart. If the heart is explanted, incise the PA at the PA bifurcation. Do not divide the PA bifurcation. If the heart is not explanted, incise the PA at the RVOT just proximal to the pulmonary valve. Ensure that the left atrial cuff is still intact. Inject cold Perfadex (2 liters total) into the retrograde pulmonary veins. Incise the pericardium bilaterally at the level of the diaphragm and transversely completely separate the pericardium from the diaphragm. Incise the inferior pulmonary ligaments on both sides. Dissect the posterior pericardium cranially from the posterior longitudinal membrane to the tracheal carina. Dissect the trachea cranially to the level of the cricoid cartilage. Retract the endotracheal tube to the level of the larynx. 50% FiO 2 In this procedure, the lungs are inflated to 50% of the total lung capacity. The trachea is divided above the cricoid cartilage with two staple loads. The posterior trachea is dissected caudal to the posterior mediastinum (esophagus) towards the diaphragm. The left PA is dissected from the aortic arch and the ligamentum arteriosum is divided. The lungs are removed and stored in ice-cold Perfadex solution. If a heart is being procured for transplant, 10 cm of the donor descending aorta is resected and placed in the same cold Perfadex solution bag as the lungs. This will later be used to reconstruct the pulmonary artery.

[0075] Ex-vivo lung perfusion (EVLP) The main principle of EVLP consists of perfusing and ventilating the extracorporeal lung in a closed container that maintains the temperature, moisture and sterility of the donor organ. The EVLP circuit consists of a centrifugal pump that circulates the perfusate through a membrane gas exchanger and a leukocyte reduction filter before entering the pulmonary artery (PA). This system is very similar to that used in extracorporeal circuits (ECC) in cardiac surgery. Acellular Steen's solution is used as the perfusate for the EVLP process.

[0076] Briefly, the process of EVLP is as follows: The lungs are placed in a specially lined plastic chamber to hold the lungs in a stable position during ventilation and to provide a warm, moist environment. Perfusate (propelled by a centrifugal pump) enters the lungs through a cannula placed in the pulmonary artery (PA). Return flow from the lungs is passive, by gravity, via the pulmonary vein (PV), and the perfusate is collected in a reservoir before being recirculated through the pump and membrane oxygenator. The gas oxygenator is connected to a tank with a special gas mixture of oxygen (6%), carbon dioxide (8%), and nitrogen (86%). An airway to the lungs is provided by a ventilator and is also connected to a tracheal chest tube.

[0077] Lung grafts (cooled during organ harvesting and undergoing static hypothermic storage) are gradually rewarmed over a period of 45 min. Lung perfusion is initiated at a low flow rate (0.10-0.15 l / min) and then gradually increased in parallel with rewarming to a pulmonary arterial supply of 40-50% of the estimated cardiac output (at 70 ml / kg / min). PA pressures should be kept low (<15-20 mmHg) once the capillary-alveolar barrier is weakened by ischemia-reperfusion injury (IRI) after organ procurement, as IRI can compromise the integrity and increase the permeability of the alveolar-capillary membrane, leading to the formation of pulmonary edema.

[0078] During the rewarming phase, O 2 The supply is delivered by a membrane oxygenator, followed by a pCO2 level close to that normally measured in PA. 2 and pH. Catheters are placed in situ to continuously measure PA and left atrial (LA) pressure throughout the process of EVLP. Once the perfusate temperature reaches 32 degrees Celsius (usually approximately 30 minutes after the start of perfusion), mechanical ventilation of the lungs is initiated.

[0079] Below is a 19-step progression of the EVLP process. This is not a comprehensive protocol but a quick reference guide.

[0080] Step 1. Transporting lungs to XPS to comply with UNOS standards.

[0081] Step 2. Cannulation of the lungs. Trim the LA cannula (green) to the appropriate atrial opening and suture with a continuous polypropylene suture. The PA cannula (yellow) opens the PA lumen to insert the XVIVO cannula. If pulmonary artery reconstruction is required, suture a segment of the donor's descending aorta to the pulmonary artery, then cannulate as above. Use umbilical tape or silk ties to secure the cannula in place on the globe and return the tie to the cannula below the pressure line. For intubation, clamp the trachea to prevent constriction. Insert an ET tube into the trachea and secure with umbilical tape or silk ties.

[0082] Step 3. Flush the back table with 1 liter of cold Perfadex and check for leaks around the cannulation. Keep the ET tube clamped.

[0083] Step 4. System setup. Set up the perfusion circuit of the XPS on the PGM. Open the dome by removing the plastic, then the first blue layer wrapping on the back table. Place a clear U-shaped drape on the top bar of the XPS on the blue table and secure the w-clips of the XPS covering the blue table. The opening of the "U" of the U-shaped drape should be on the right side so the tubing can pass through. Aseptically open the second blue layer of the dome on the blue table of the Xvivo machine. Attach the red 3 / 8 inch drain line to the back of the dome and run the quarter line around the outside of the pole and into the red roller pump. Release the drain bag and attach the orange and red lines to the bag. Add a return line from the top of the reservoir to the two-way stopcock. Close the two-way stopcock to the reservoir on the red line and open it to the drain bag. Set the transducer, flush with sterile saline, add blue tubing to the heater / cooler, then add an intravenous gas line to the back of the Quadrox. Add sufficient O 2 Make sure there is a trigger.

[0084] Step 5. Purge the system. Add 1500ml of STEEN to the reservoir, add medications (Heparin 10,000 units, Methylprednisolone 500mg, Ceftazidine 1gm) and turn on Cardiohelp and heater-cooler (set to 23) first, followed by UPS, touch screen, and ventilator. Purge the perfusion circuit by removing the yellow cap on the back of the Quadrox, the clear cap on one of the reservoirs, and the blue cap on the leukofilter. Increase Cardiohelp to 1000RPM to check for leaks in the circuit, after 1 minute increase Cardiohelp to 3000RPM. After a few minutes increase Cardiohelp to 5000RPM and run for 1 minute to ensure all air is out of the lines, then reduce RPM to less than 250.

[0085] Step 6. Logging Data Settings. Enter the required information on the touch screen setup page and change the PH to an acceptable level up to alarm (6.8). On the service page, press the green PGM calibration button and enter the PH and PO2 based on the calibration number on the PGM packaging. Set the timers on the main screen (#1 and #2 count up, #3 count down (set #3 to 10 minutes)). Press Set for Ventilator, press Confirm in Mode (S) CMV+. Enter the spreadsheet parameters and press Confirm. Also set alarms for each of the flowsheet parameters. On the I / O panel on the back of the XPS, place the inspiratory port on the right side of the lung circuit and the expiratory port (blue tip) on the left side. Connect the flow sensor tubing, white to clear and blue to blue. Connect the venous gas mix line. High pressure O 2 Connect the lines. The humidification filter is placed at the lung end of the circuit between the flow sensor and the ET-T. Perform the pre-op check, press System, press Test Calibration. Select each calibration test, one at a time. Press Airtightness and the steps below, Press Flow Sensor and the steps below, O 2 The cells do not need to be tested.

[0086] Step 7. Retrograde flush. Using a sterile tubing clamp, change the flow direction in the perfusion circuit so that the flow goes in the LA and exits the PA. Starting at 750 RPM, slowly increase the RPM until there is enough flow to fill the PA cannula, flushing the lungs until there is approximately 250cc of STEEN solution minus blood. Use the recycle pump to direct this STEEN solution to the dump bag. Once the blood has been cleared, attach the cannula and circuit to the LA side and ensure the lungs are filled with STEEN solution. There should be enough STEEN through the LA cannula to fill the PA cannula, then reset the direction of the recycle pump to go into the reservoir. Reposition the sterile clamp on the top of the PA cannula and attach it to the circuit. Clamp the bridge (should be the only clamp).

[0087] Step 8. Calibrate. Calibrate the perfusion flow sensor and pressure sensor. (The flow sensor can be done before the lung is placed in the circuit for retrograde). The pressure sensor should be done immediately after the lung is on the circuit for retrograde (top of fluid height - where the cannula meets the lung and pressure two-way stopcock, pull the syringe from the pressure sensor line to get them all at the same height, fill with STEEN, making sure to move the two-way stopcock to block off saline).

[0088] Step 9. Antegrade. Start Timer 1 (perfusion timer) and follow the EVLP work-up sheet for settings for the first hour.

[0089] Step 10. Settings for the first hour. Every 10 minutes, Cardiohelp and Heater-Cooler are changed until they reach their maximum values. Ventilation cannot start until the temperature reaches 32°C. At 32°C, the bronchi may be processed. The trigger gas sweep must start at the same time as the ventilator is started.

[0090] Step 11. Refilling the lungs. 2To avoid confusion with the challenge, lung recruitment is achieved by manually holding the expiratory key on the ventilator for 15 seconds. To hold the exhalation, this key should be pressed after the inspiration.

[0091] Step 12.O 2 Challenge.O 2 During the challenge, only change the ventilator settings and follow the supplemental settings on the EVLP workup sheet (multiply Vt by IBW x 10, increase FiO2 to 100%, and increase BPM to a maximum of 10).

[0092] Step 13. Degas. 2 At the last moment of the challenge, arterial and venous perfusate samples should be taken from the transducers. Press the grey PH button on the main screen to lock the gas values. (When results are returned from the lab, perform pinpoint calibrations for PH on both LA and PA.) Record the appropriate information, then reset to normal settings on the ventilator (keep alarms and settings high at this point).

[0093] Step 14. X-ray. 2 After the challenge is complete, an x-ray needs to be performed to provide a baseline comparison for future x-rays.

[0094] Step 15. Dilute STEEN. After refilling, challenge, gas aspiration, and x-ray are complete (or between x-rays), dilution of STEEN is required. Open the + / - Pump Control window on the touch screen. Touch the Remove button and slide your finger down until the remove button locks (if the clamp method is used, remove the clamp instead). Watch the reservoir level drop. Once enough STEEN has been removed, touch the Remove button to shut off (replace the clamp if the clamp method is used). Add 3 or 4 fresh vials of STEEN. You may also add another dose of drug.

[0095] Step 16. Maintain and evaluate the lungs for the next 3-5 hours. Repeat steps 12 and 13 (subtract pinpoint calibration) at the 50 minute mark of each hour.

[0096] Step 17. Repeat step 14 approximately 1 hour before the lung is to be removed for transplant. Comparing the first x-ray with the second x-ray will help determine if the lung is suitable for transplant.

[0097] Step 18. Repeat step 15 after 6 h of perfusion.

[0098] Step 19. Rapid cooling. Once the lung is accepted for transplant, set the heater / cooler to 15°C and when the lung is 50% inflated at 32°C, clamp the ET tube, disconnect the lung from the perfusion circuit, flush with 2 liters of cold Perfadex, and place in a sterile bag with the Perfadex (as per standard donor procurement protocol).

[0099] Step 20. Clean and store the XPS. Wipe down the surface of the XPS with disinfectant and store it with the toggle switch in the up position and plugged in for charging. Gas should be drawn at the end of each 10 minute challenge.

[0100] For reference, see Figures 1 and 2, which show schematic diagrams of potential systems.

[0101] Example 2 Inhaled nitric oxide improves brain mitochondrial function in a blinded, randomized, controlled piglet asphyxia model of cardiac arrest study.

[0102] Introduction Neurological injury after pediatric cardiac arrest (CA) remains common. Inhaled nitric oxide (iNO) may attenuate cerebral mitochondrial dysfunction, an important convergence point for secondary brain injury induced by CA. We hypothesized that animals treated with 20 ppm iNO after asphyxia and cardiac arrest, during CPR and 4 hours of return of spontaneous circulation (ROSC), would improve cerebral blood flow (CBF) and improve mitochondrial function, as defined by increased respiratory control ratio (RCR) and reduced mitochondrial reactive oxygen species (mtROS) compared to placebo.

[0103] method Four-week-old pigs were asphyxiated for 7 min and then put into ventricular fibrillation. Guideline CPR was performed with a compression depth (CD) of ≥1 / 3 of the chest diameter, and standard epinephrine was continued for 10 min or until ROSC, with protocolized care after ROSC. Subjects were randomized (starting with 20 ppm iNO at 1 min into the CPR period, n=10, or placebo, n=10) in a blinded fashion. Shams (n=4) did not receive CA or CPR. Baseline and continuous CBF measurements were made using invasive clinical and noninvasive optical devices. Cortical and hippocampal tissues were analyzed by high-resolution respirometry to assess mitochondrial function. T-tests and ANOVAs were used where applicable. Longitudinal hemodynamic variables were compared using generalized estimating equations to control for within-subject correlations.

[0104] result 7 / 10 in the placebo group and 10 / 10 in the iNO group (p=0.21) survived. There were no significant differences in invasive or non-invasive CBF between treatment groups during CPR and after ROSC. RCR in the cortex and hippocampus was significantly higher (p=0.04, 0.007), and mtROS production was significantly lower in iNO-treated animals (p<0.001, p=0.03). There were no differences in systemic or pulmonary hemodynamics between the iNO and placebo groups, but the mean pulmonary artery pressure in iNO animals during CPR tended to be lower (28.1±9.8v vs. 42.6±6.0, p=0.14). iNO preserves cerebral mitochondrial function (increased RCR) and limits mtROS production in a porcine model of pediatric CA. Further studies are needed to evaluate this potential neuroprotective effect of iNO in ischemia-reperfusion injury and cardiac arrest.

Claims

[Claim 1] Systems, devices, methods, etc.

Citation Information

Patent Citations

  • S-nitrosoprotein containing fatty acid and method for producing the same

    JP2008050294A

  • Administration and Monitoring of Nitric Oxide in Ex Vivo Liquids

    JP2017503762A

  • Administration and monitoring of nitric oxide in ex vivo fluids

    US20170215411A1